BBHC
CAPR icon

Brown Brothers Harriman & Co’s Capricor Therapeutics CAPR Stock Holding History

Brown Brothers Harriman & Co’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-5,112
Closed -$24 – 1158
2021
Q1 		$24 Buy
+5,112
New +$29.4K ﹤0.01% 756

Other funds holding CAPR

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Brown Brothers Harriman & Co's CAPR Position: Q2 2021 in Review

Brown Brothers Harriman & Co sold out of Capricor Therapeutics (CAPR) in Q2 2021, closing a stake of 5,112 shares — an estimated $24 sold.

Brown Brothers Harriman & Co first reported a position in CAPR in Q1 2021 and held it in 1 quarter. The position peaked at $24 in Q1 2021. 31 funds tracked by Wall St. Rank hold CAPR as of Q2 2021.

  • Brown Brothers Harriman & Co reported no remaining Capricor Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Brown Brothers Harriman & Co sold 5,112 Capricor Therapeutics shares in Q2 2021, an estimated $24.
  • Brown Brothers Harriman & Co first reported a position in Capricor Therapeutics in Q1 2021 and held it in 1 quarter.
  • Brown Brothers Harriman & Co's Capricor Therapeutics position peaked at $24 in Q1 2021.
  • 31 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2021.

Based on Brown Brothers Harriman & Co's 13F filing for Q2 2021, filed 13 Aug 2021.